Androgen decline and outcome in castration resistant prostate cancer(mCRPC) patients treated with docetaxel (Doc), prednisone1/-bevacizumab (B)

Authors

C. J. Ryan, Masonic Cancer Center
S. Dutta, Duke University
W. Kelly, Thomas Jefferson UniversityFollow
M. J. Morris, Medicine, Memorial Sloan-Kettering Cancer Center
M-E. Taplin, Dana-Farber Cancer Institute
S. Halabi, Duke University

Document Type

Article

Publication Date

10-2018

Comments

This article is the author’s final published version in Annals of Oncology, Volume 29, Supplement 8, October 2018, Page viii283.

The published version is available at https://doi.org/10.1093/annonc/mdy284.025. Copyright © Ryan et al.

Recommended Citation

Ryan, C. J.; Dutta, S.; Kelly, W.; Morris, M. J.; Taplin, M-E.; and Halabi, S., "Androgen decline and outcome in castration resistant prostate cancer(mCRPC) patients treated with docetaxel (Doc), prednisone1/-bevacizumab (B)" (2018). Department of Medical Oncology Faculty Papers. Paper 116.
https://jdc.jefferson.edu/medoncfp/116

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID

32136650

Language

English